prof.dr. M.J. IJzerman (Maarten)

Social Sciences

# Cancer
# Health Economics

Medicine & Life Sciences

# Cost-Benefit Analysis
# Costs And Cost Analysis
# Decision Support Techniques
# Delivery Of Health Care
# Economics
# Health

Faculty of Behavioural, Management and Social Sciences (BMS), Health Technology & Services Research (HTSR)

Erasmus University Rotterdam
Academic, fulltime position
Laboratorium Microbiologie
Raad van Toezicht
University of Melbourne
Academic research

Vu, M., Degeling, K., Thompson, E. R., Blombery, P., Westerman, D. , & IJzerman, M. J. (2024). Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. Applied health economics and health policy, 22, 107-122. https://doi.org/10.1007/s40258-023-00826-4

Behr, C. , Koffijberg, H. , IJzerman, M., Kauczor, H. U., Revel, M. P., Silva, M., von Stackelberg, O. , van Til, J., & Vliegenthart, R. (2023). Willingness to participate in combination screening for lung cancer, chronic obstructive pulmonary disease and cardiovascular disease in four European countries. European radiology. Advance online publication. https://doi.org/10.1007/s00330-023-10474-w

Glewis, S., Krishnasamy, M., Lingaratnam, S., Harris, S., Underhill, C., Georgiou, C., Warren, M., Campbell, R. , IJzerman, M., Fagery, M., Campbell, I., Martin, J. H., Tie, J., Alexander, M., & Michael, M. (2023). Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey. Clinical and Translational Science, 16(12), 2700-2708. https://doi.org/10.1111/cts.13664

Field, K. M., Andrew Rosenthal, M., Gillett, P. , & IJzerman, M. (2023). Assessing neuro-oncology clinical trial impact and value: Testing a novel multi-criteria decision analysis app. Journal of Clinical Neuroscience, 118, 70-78. https://doi.org/10.1016/j.jocn.2023.07.024

Gillett, P., Mahar, R. K., Tran, N. R., Rosenthal, M. , & IJzerman, M. (2023). Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value. Cost effectiveness and resource allocation, 21(1), Article 87. https://doi.org/10.1186/s12962-023-00496-y

Khorshidi, H. A., Marshall, D., Goranitis, I., Schroeder, B. , & IJzerman, M. (2023). System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. Expert Review of Pharmacoeconomics and Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2023.2267764

Drosdowsky, A., Lamb, K. E., Karahalios, A., Bergin, R. J., Milley, K., Boyd, L. , IJzerman, M. J., & Emery, J. D. (2023). The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose–response meta-analysis. British journal of cancer, 129(6), 993-1006. https://doi.org/10.1038/s41416-023-02377-w

Ven, M. V. D. , Koffijberg, H. , Retèl, V. P. J. , Harten, W. H. V. , & IJzerman, M. J. (2023). Dynamic Simulation Modeling to Analyze the Impact of Whole Genome Sequencing National Implementation Scenarios in Lung cancer on Time-to-Treatment, Costs and Patient Demand. MedRxiv. https://doi.org/10.1101/2023.11.10.23298371

Berghuis, A. M. S. , Koffijberg, H. , Pouwels, X. G. L. V., Berger, F., Alix-Panabières, C., Jacot, W., Pierga, J. Y., Bidard, F. C. , & IJzerman, M. J. (2023). Cost-effectiveness of CTC guided chemo- or endocrine therapy in ER+ HER2- metastatic breast cancer – results from a randomized controlled multicenter trial. https://doi.org/10.1101/2023.10.09.23296711

van Delft, F. A., Schuurbiers, M. M. F., Muller, M., Burgers, S., van Rossum, H. H. , IJzerman, M. J., van den Heuvel, M. M. , & Koffijberg, H. (2023). Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer. Tumor Biology. https://doi.org/10.3233/TUB-220022

Bekijk alle publicaties van deze medewerker

Naar mijn profiel

Master

Industrial Engineering and Management

Vakken in het huidig collegejaar worden toegevoegd op het moment dat zij definitief zijn in het Osiris systeem. Daarom kan het zijn dat de lijst nog niet compleet is voor het gehele collegejaar.